Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states

      This paper is only available as a PDF. To read, Please Download here.


      A total of 28 hyperlipoproteinaemic patients (8 type IIA, 12 type IIB and 8 type IV)were studied. Each patient was put on a ‘prudent’ isocaloric diet (50% carbohydrate, 30% fat, 20% protein) following a 2-month period of wash-out. Fenofibrate (300 mg/day) was then given for 2 periods of 2 months, each separated by a 2-month period in which only the dietary treatment was continued. Fenofibrate induced a significantly beneficial effect on the abnormal plasma levels of lipids and apolipoproteins A-1 and B in all three phenotypes. Total cholesterol significantly decreased in type IIA and IIB; total triglycerides decreased significantly in all three types. HDL-C increased in all the patients but significantly only in those presenting types IIB and IV. ApoB significantly decreased in the 3 groups while apoA-I increased. The ratio apoA/apoB increased significantly in the three groups. Enzymatic parameters did not vary during the drug treatment. However, 6 patients (16%) dropped out because of gastro-intestinal side effects.



      Apo = apolipoprotein (), C = cholesterol (), HDL = high density lipoproteins (), LDL = low density lipoproteins (), TG = triglycerides ()
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Brouin P.
        • Mejean L.
        • Sauvanet H.P.
        • Pointel J.P.
        • Derry G.
        Etude de I'action hypolipemiante du procbtofene chez des malades porteurs d'une HLP de type IIA ou IIB.
        Gaz. Med. France. 1976; 83: 3848
        • Mordasini R.
        • Granjean E.M.
        • Nobile E.M.
        • Beaumgartner G.
        • Riva G.
        Procetofen — Eine Alternative in der Behandlung der Hypercholesterolamie?.
        Schweiz. Med. Wschr. 1979; 100: 1140
        • Ruffy J.
        A propos du traitment de 100 observations d'hyperlipoprot6in6mies essentielles athérogènes.
        Sem. Hôp. Paris Thér. 1975; 51: 467
        • Micheli H.
        • Pometta D.
        • Gustafson A.
        Procetofen in four types of hyperlipoproteinemia — Effect on apoA and apoB lipoproteins.
        in: Noseda G. Lewis B. Paoletti R. Diet and Drugs in Atherosclerosis. Raven Press, New York1980: 97
        • Patrassi G.
        • Avogaro P.
        • Crepaldi G.
        Rationale for a dietary treatment of atherosclerosis.
        Giorn. Aterioscl. 1967; 5: 307
        • Kostner G.M.
        • Avogaro P.
        • Bittolo Bon G.
        • Cazzolato G.
        • Quinci G.B.
        Determination of high density lipoproteins — Screening methods compared.
        Clin. Chem. 1979; 25: 939
        • Avogaro P.
        • Bittolo Bon G.
        • Cazzolato G.
        • Quinci G.B.
        • Sanson A.
        • Sparla M.
        • Zagatti G.C.
        • Caturelli G.
        Variations in apolipoproteins B and A-I in the course of acute myocardial infarction.
        Europ. J. Clin. Invest. 1978; 8: 121
        • Metropolitan Life Insurance Co.
        Statistical Bulletin No. 40, Nov.–Dec. 1959.
        in: Documenta Geigy, Tables Scientifiques VI. Ed. Basle, 1963: 634
        • Beaumont J.L.
        • Carlson L.A.
        • Cooper G.R.
        • Fejfar Z.
        • Fredrickson D.S.
        • Strasser T.
        Classification of hyperlipidemias and hyperlipoproteinemias.
        WHO Bull. 1970; 43: 891
        • Snedecor G.W.
        • Cochran W.G.
        Statistical Methods.
        in: 6th edition. Iowa State University Press, Ames, IA1967: 172-198
        • Snedecor G.W.
        • Cochran W.G.
        Statistical Methods.
        in: 6th edition. Iowa State University Press, Ames, IA1967: 381-418
        • Strisower E.H.
        • Adamson C.
        • Strisower B.
        Treatment of hyperlipidemic states.
        Med. Clin. N. Amer. 1970; 54: 1959
        • Mordasini R.
        • Keller M.
        • Riesen W.F.
        Effect of probucol and diet on serum lipids and lipoprotein fractions in primary hypercholesterolemia.
        in: Noseda G. Lewis B. Paoletti R. Diet and Drugs in Atherosclerosis. Raven Press, New York1980: 181
        • Sniderman A.
        • Shapiro G.
        • Marpole D.
        • Skinner B.
        • Teng B.
        • Kwiterovich Jr., P.O.
        Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low density (B) lipoproteins).
        in: Proc. Nat. Acad. Sci. (USA). 77. 1980: 604
        • Schaefer E.J.
        • Heaton H.H.
        • Wetzel M.G.
        • Brewer Jr., B.H.
        Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease.
        Arteriosclerosis. 1982; 2: 16
        • Norum R.A.
        • Lakier J.B.
        • Goldstein S.
        • Angel A.
        • Goldberg R.N.
        • Block W.D.
        • Noffze D.Z.
        • Dolphin P.J.
        • Edelglass J.
        • Bogorad D.D.
        • Alaupovic P.
        Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease.
        N. Engl. J. Med. 1982; 306: 1513